Next Article in Journal
PET-Guided Surgery — High Correlation between Positron Emission Tomography with 11C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours
Next Article in Special Issue
Desmoid Tumors in Pregnant and Postpartum Women
Previous Article in Journal
Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
Previous Article in Special Issue
Surgical Treatment of Intra-Abdominal Desmoid Tumors Resulting In Short Bowel Syndrome
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(1), 88-99;

Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality

Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, 65-Tsurumai, Showa, Nagoya 466-8550, Japan
Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan
Author to whom correspondence should be addressed.
Received: 21 November 2011 / Revised: 4 January 2012 / Accepted: 3 February 2012 / Published: 7 February 2012
(This article belongs to the Special Issue Desmoid Tumors)
Full-Text   |   PDF [505 KB, uploaded 7 February 2012]   |  


Treatment modalities for desmoid tumors have been changed because of the high recurrence rate, even after wide resection, and some cases experience spontaneous self-regression during clinical course. The treatment modality in our institutions before 2003 was surgical resection with wide surgical margin, however, meloxicam, which is a NSAID and a selective COX-2 inhibitor has been applied consecutively since 2003. We reviewed the previously reported outcomes of surgical and conservative treatment in our institutions. Among 30 patients receiving surgical treatment, 16 (53%) recurred. Younger age ( p < 0.05) was a significant poor factor. According to RECIST for meloxicam treatment, CR was in one, PR in 10, SD in eight, PD in one evaluated at 2011. Older age ( p < 0.01) was significantly associated with good outcome for meloxicam treatment. Results of the previous study indicated that surgical treatment alone could not control desmoid tumors, even with negative surgical margin. Considering the functional impairment resulting from surgery with negative surgical margin, a conservative and effective treatment modality with fewer complications is desired. Conservative treatment with meloxicam is a promising novel modality for patients with extra-abdominal desmoid tumors. View Full-Text
Keywords: extra-abdominal desmoids; meloxicam; COX-2; conservative therapy; surgery extra-abdominal desmoids; meloxicam; COX-2; conservative therapy; surgery

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Nishida, Y.; Tsukushi, S.; Shido, Y.; Urakawa, H.; Arai, E.; Ishiguro, N. Transition of Treatment for Patients with Extra-Abdominal Desmoid Tumors: Nagoya University Modality. Cancers 2012, 4, 88-99.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top